Novel assay platform for 3D microfluidic cancer research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

CAR-T cells are genetically modified T-cells used to find and kill cancer cells by targeting specific cancer-associated proteins, or antigens. CAR-T cell therapy is highly effective against hematological malignancies, but faces challenges in solid tumors due to the immunosuppressive effects of the tumor microenvironment. Often, combination therapies, such as chemotherapy and checkpoint blockage, are used in combination with CAR-T to improve efficacy.

UoS and ScreenIn3D researchers developed novel miniaturized screening assays that use very small amounts of CAR-T cells within 3D complex in vitro models of solid tumors on a chip. This exciting technological advance enables investigation of CAR-T efficacy, off-target cytotoxicity, and synergistic effects when used in combination assays.

AMSBIO offers a custom service that enables researchers to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various hematological malignancies. Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO can help design, plan and execute your CAR-T study, whether you are in the preclinical, clinical, or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, allowing you to start with a target molecule (Phase I) or antibody (Phase II).

As part of their custom CAR-T development service, AMSBIO construct the single chain variable fragment (ScFv), transfer it into a CAR lentivector of your choice, make the lentivirus, and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analyzed and cytokine production quantified.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>